{
  "meta": {
    "data_length": 2,
    "message": "Statements retrieved successfully",
    "request_url": "http://api.moalmanac.org/statements?proposition_id=125&agent_id=fda&agent_id=ema",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.028037,
    "timestamp_received": "2026-05-13T16:26:22.573562+00:00Z",
    "timestamp_returned": "2026-05-13T16:26:22.601599+00:00Z",
    "trace_id": "18b15cde-2d51-4769-bc19-693ab1a1fa8f"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-05-07"
  },
  "data": [
    {
      "id": 1051,
      "type": "Statement",
      "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
      "contributions": [
        {
          "id": 13,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Adding EMA approvals for use to database",
          "date": "2024-10-20"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema.balversa",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Balversa (erdafitinib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/medicines/human/EPAR/balversa",
            "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-05",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.ema.europa.eu/en/medicines",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Janssen-Cilag International N.V.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Balversa",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "erdafitinib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2024-08-29",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-08-29",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:ema.balversa:0",
        "indication": "Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.",
        "initial_approval_date": "2024-08-22",
        "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/balversa-epar-public-assessment-report_en.pdf",
        "description": "The European Medicines Agency (EMA) has authorized erdafitinib for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting. This indication is based on BLC3001 Study Cohort 1, a Phase 3, randomised, open-label, multicentre study, where eligible patients were required to have at least one of the following FGFR fusions: FGFR2::BICC1, FGFR2::CASP7, FGFR3::TACC3, FGFR3::BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.",
        "raw_biomarkers": null,
        "raw_cancer_type": "urothelial carcinoma",
        "raw_therapeutics": "Balversa (erdafitinib)",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:ema.balversa",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Balversa (erdafitinib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.",
          "urls": [
            "https://www.ema.europa.eu/en/medicines/human/EPAR/balversa",
            "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-05",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.ema.europa.eu/en/medicines",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Janssen-Cilag International N.V.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Balversa",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "erdafitinib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2024-08-29",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-08-29",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 125,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 100,
            "name": "FGFR3 p.S249C",
            "genes": [
              {
                "id": 24,
                "name": "FGFR3",
                "primaryCoding": {
                  "id": "hgnc:3690",
                  "code": "HGNC:3690",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690"
                  ]
                },
                "mappings": [
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000068078",
                      "code": "ENSG00000068078",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000068078"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:2261",
                      "code": "2261",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/2261"
                      ]
                    }
                  },
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_000142.5",
                      "code": "NM_000142.5",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "4p16.3"
                  },
                  {
                    "name": "location_sortable",
                    "value": "04p16.3"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Somatic Variant"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "chromosome",
                "value": "4"
              },
              {
                "name": "start_position",
                "value": 1803568
              },
              {
                "name": "end_position",
                "value": 1803568
              },
              {
                "name": "reference_allele",
                "value": "C"
              },
              {
                "name": "alternate_allele",
                "value": "G"
              },
              {
                "name": "cdna_change",
                "value": "c.746C>G"
              },
              {
                "name": "protein_change",
                "value": "p.S249C"
              },
              {
                "name": "variant_annotation",
                "value": "Missense"
              },
              {
                "name": "exon",
                "value": "6"
              },
              {
                "name": "rsid",
                "value": "rs121913483"
              },
              {
                "name": "hgvsg",
                "value": "4:g.1803568C>G"
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 8,
          "conceptType": "Disease",
          "name": "Bladder Urothelial Carcinoma",
          "primaryCoding": {
            "id": "oncotree:BLCA",
            "code": "BLCA",
            "name": "Bladder Urothelial Carcinoma",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 110,
          "conceptType": "Drug",
          "name": "Erdafitinib",
          "primaryCoding": {
            "id": "ncit:C103273",
            "code": "C103273",
            "name": "Erdafitinib",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "25.01d",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273"
            ]
          },
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "rxcui:2123125",
                "code": "2123125",
                "name": "erdafitinib",
                "system": "RxNorm",
                "systemVersion": "02-Mar-2026",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2123125"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:1511250",
                "code": "1511250",
                "name": "erdafitinib",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1511250"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "sctid:787731007",
                "code": "787731007",
                "name": "Erdafitinib",
                "system": "SNOMED",
                "systemVersion": "2025-03-01",
                "iris": [
                  "https://browser.ihtsdotools.org/?perspective=full&conceptId1=787731007&edition=MAIN/2025-03-01&release=&languages=en"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:37204108",
                "code": "37204108",
                "name": "Erdafitinib",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/37204108"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "FGFR inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ]
        }
      }
    },
    {
      "id": 143,
      "type": "Statement",
      "description": "The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
      "contributions": [
        {
          "id": 0,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Initial access of FDA approvals",
          "date": "2024-10-30"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:fda.balversa",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Balversa (erdafitinib) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Janssen Products, LP.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Balversa",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "erdafitinib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 212018,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-01-19",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:fda.balversa:0",
        "indication": "BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
        "initial_approval_date": "2024-01-19",
        "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf",
        "description": "The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",
        "raw_biomarkers": "susceptible FGFR3 genetic alterations",
        "raw_cancer_type": "locally advanced or metastatic urothelial carcinoma (mUC)",
        "raw_therapeutics": "Balversa (erdafitinib)",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:fda.balversa",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Balversa (erdafitinib) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Janssen Products, LP.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Balversa",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "erdafitinib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": null,
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 212018,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-01-19",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 125,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 100,
            "name": "FGFR3 p.S249C",
            "genes": [
              {
                "id": 24,
                "name": "FGFR3",
                "primaryCoding": {
                  "id": "hgnc:3690",
                  "code": "HGNC:3690",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690"
                  ]
                },
                "mappings": [
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000068078",
                      "code": "ENSG00000068078",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000068078"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:2261",
                      "code": "2261",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/2261"
                      ]
                    }
                  },
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_000142.5",
                      "code": "NM_000142.5",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "4p16.3"
                  },
                  {
                    "name": "location_sortable",
                    "value": "04p16.3"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Somatic Variant"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "chromosome",
                "value": "4"
              },
              {
                "name": "start_position",
                "value": 1803568
              },
              {
                "name": "end_position",
                "value": 1803568
              },
              {
                "name": "reference_allele",
                "value": "C"
              },
              {
                "name": "alternate_allele",
                "value": "G"
              },
              {
                "name": "cdna_change",
                "value": "c.746C>G"
              },
              {
                "name": "protein_change",
                "value": "p.S249C"
              },
              {
                "name": "variant_annotation",
                "value": "Missense"
              },
              {
                "name": "exon",
                "value": "6"
              },
              {
                "name": "rsid",
                "value": "rs121913483"
              },
              {
                "name": "hgvsg",
                "value": "4:g.1803568C>G"
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 8,
          "conceptType": "Disease",
          "name": "Bladder Urothelial Carcinoma",
          "primaryCoding": {
            "id": "oncotree:BLCA",
            "code": "BLCA",
            "name": "Bladder Urothelial Carcinoma",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 110,
          "conceptType": "Drug",
          "name": "Erdafitinib",
          "primaryCoding": {
            "id": "ncit:C103273",
            "code": "C103273",
            "name": "Erdafitinib",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "25.01d",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273"
            ]
          },
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "rxcui:2123125",
                "code": "2123125",
                "name": "erdafitinib",
                "system": "RxNorm",
                "systemVersion": "02-Mar-2026",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2123125"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:1511250",
                "code": "1511250",
                "name": "erdafitinib",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1511250"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "sctid:787731007",
                "code": "787731007",
                "name": "Erdafitinib",
                "system": "SNOMED",
                "systemVersion": "2025-03-01",
                "iris": [
                  "https://browser.ihtsdotools.org/?perspective=full&conceptId1=787731007&edition=MAIN/2025-03-01&release=&languages=en"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:37204108",
                "code": "37204108",
                "name": "Erdafitinib",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/37204108"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "FGFR inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ]
        }
      }
    }
  ]
}